Breaking News

Valeant To Buy Bausch & Lomb

May 27, 2013

Valeant Pharmaceuticals International will pay $8.7 billion to acquire Bausch & Lomb, the eye care company. Under the terms of the deal, Valeant will pay $4.5 billion to the investor group that owns Bausch & Lomb, led by private equity firm Warburg Pincus. It will also spend about $4.2 billion to repay Bausch & Lomb’s debt.

 

The agreement continues the flurry of deal-making in the health care industry, as companies seek to buy the growth they are hard-pressed to generate on their own. Announced merger volume in the sector this year is up 14% from the period a year earlier, even as takeovers have fallen 8%.


This acquisition follows Valeant's April purchase for Obagi skin care for $348 million.

 

Related End-User Markets:

blog comments powered by Disqus
  • Innovation On Display

    Melissa Meisel, Associate Editor||February 3, 2016
    P&G Beauty Digital Studio showcases new products for 2016

  • Testing for Sustainable Preservatives

    Adam P. Byrne, William Michael Hart-Cooper, Kaj Johnson, Larry H. Stanker, Dominic W. S. Wong, William J. Orts||January 4, 2016
    A rapid, inexpensive and qualitative protocol for determining microbial growth inhibition.

  • Burgeoning Beauty

    Burgeoning Beauty

    Melissa Meisel, Associate Editor||January 4, 2016
    A look at trailblazers for 2016 and beyond.